Healthcare / Health Information ServicesTokyo
$266.00
+3.00 (+1.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-430.7M · quality 38.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-198.2%
↓Gross Margin
70.6%
↑Debt/Equity
2.22
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.4%
FCF CAGR
—
FCF margin
-67.8%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $635.7M · net income $-539.7M · FCF $-430.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $635.7M | $635.7M | $528.0M | $575.5M | $1.05B |
| Net Income | $-539.7M | $-539.7M | $-804.6M | $-505.3M | $33.9M |
| EBITDA | $-500.3M | $-500.3M | $-792.8M | $-500.0M | $40.3M |
| EPS | — | — | -98.61 | -64.51 | 4.33 |
| Gross Margin | 70.6% | 70.6% | 71.9% | 65.4% | 71.9% |
| Operating Margin | -71.2% | -71.2% | -123.9% | -76.0% | 5.8% |
| Net Margin | -84.9% | -84.9% | -152.4% | -87.8% | 3.2% |
| Balance Sheet | |||||
| Debt/Equity | 2.22 | 2.22 | 0.25 | 0.00 | 0.01 |
| Current Ratio | 2.05 | 2.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-430.7M | $-430.7M | $-776.2M | $-258.7M | $-146.9M |
| Returns | |||||
| ROE | -198.2% | -198.2% | -99.3% | -46.3% | 2.7% |
| Valuation | |||||
| P/E | — | — | — | — | 82.22 |
| EV/EBITDA | — | — | — | — | 48.80 |
| P/B | 8.08 | 8.08 | 3.39 | 4.69 | 2.19 |
| Growth & Yield | |||||
| Revenue Growth | 20.4% | 20.4% | -8.2% | -45.2% | — |
| EPS Growth | — | — | -52.9% | -1589.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-98.61 → n/d
Residual
-23.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.